IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a fast-growing and malignant cancer that responds well to chemotherapy; however, the survival rate is less than 15% after 2 years of diagnosis. Therefore, novel therapeutic agents for treating SCLC patients need to be evaluated. This study aims to identify the therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Mi-Sook, Jung, Kyungsoo, Song, Ji-Young, Sung, Min-Jung, Ahn, Sung-Bin, Lee, Boram, Oh, Doo-Yi, Choi, Yoon-La
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029374/
https://www.ncbi.nlm.nih.gov/pubmed/32099898
http://dx.doi.org/10.1016/j.omto.2019.12.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029374/
https://www.ncbi.nlm.nih.gov/pubmed/32099898
http://dx.doi.org/10.1016/j.omto.2019.12.009

Ejemplares similares